CH505 TF chTrimer

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsHIV-1

Phase 1

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

CompletedNCT04915768

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2023-01-23End: 2025-07-15Updated: 2026-02-27

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

SuspendedNCT06680479

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1

Start: 2025-04-01End: 2028-04-14Target: 30Updated: 2026-03-03

Related Papers

Safety and immunogenicity of an HIV envelope trimer immunogen that elicits CD4 binding site neutralizing antibody precursors (HVTN 300)

medRxiv2026-04-03